Stockreport

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) [Yahoo! Finance]

CERo Therapeutics Holdings, Inc.  (CERO) 
PDF SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunot [Read more]